Disease Landscape and Forecast Insights

Chronic heart failure (CHF) manifests as impaired cardiac function and consequent failure to maintain sufficient blood flow throughout the body to meet its metabolic demands. The CHF therapy market…

Chronic kidney disease (CKD) is caused by structural or functional abnormalities in the kidney that impair its ability to filter blood. The CKD drug market primarily comprises antihypertensive…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key rheumatoid arthritis patient populations, covering 171 countries and…

Clarivate Epidemiology’s coverage of rheumatoid arthritis (RA) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of RA for each…

Clarivate Epidemiology’s coverage of rheumatoid arthritis (RA) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the total and diagnosed…

Sickle cell disease (SCD) is a rare genetic blood disorder characterized by the polymerization of hemoglobin in red blood cells that distorts them into a sickle shape. This sickling leads to…

Eisai / Biogen’s Leqembi (lecanemab) and Eli Lilly’s Kisunla (donanemab) are vying to capitalize on the potential for a disease-modifying therapy (DMT) in Alzheimer’s disease (AD), and…

Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem cell disorders, which result in cytopenia and an increased risk of progression to acute myeloid leukemia (AML)…

Primary membranous nephropathy (pMN), the most common type of MN, is a rare autoantibody-mediated autoimmune kidney disease. Despite being one of the leading causes of nephrotic syndrome in…

Clarivate Epidemiology’s coverage of eosinophilic esophagitis (EoE) comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States…

Muscular dystrophy (MD) is a spectrum of genetic disorders characterized by muscle weakness that, in severe forms, can lead to loss of ambulation and early mortality. The standard treatment for MD…

Biosimilar regulations and guidance have been defined, at least in draft form, in most the world’s leading pharmaceutical markets. In many cases, biosimilar guidance is based on that of the EMA,…